Free Newsletter
Genentech, Biogen ask FDA to broaden Rituxan use
Free newsletter via e-mail
Tools
Genentech and partner Biogen Idec are asking the FDA to allow their cancer drug Rituxan to be used in combination with chemotherapy for people with chronic lymphocytic leukemia. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: